Latest news with #HerbalOasis
Associated Press
21-05-2025
- Business
- Associated Press
Herbal Oasis Expands Footprint with New Distribution Agreement in Georgia
Charlotte, North Carolina--(Newsfile Corp. - May 21, 2025) - Herbal Oasis ('Oasis'), the hemp-derived THC-infused social seltzer redefining how people connect, unwind, and celebrate life, is proud to announce a new distribution partnership with Beverage South, a leading distributor serving much of the state of Georgia. Starting this month, Oasis will be available on shelves across Georgia as the brand continues its rapid expansion across the Southeast. Georgia marks the fourth state in just two months where Oasis has launched, following successful rollouts in Alabama, Florida, and North Carolina. The partnership with Beverage South significantly strengthens Oasis's presence in one of the region's key markets. 'We're thrilled to partner with Beverage South, whose reach and reputation make them an ideal distributor for Oasis in Georgia,' said Ronan Kennedy, CEO of cbdMD, parent company of Oasis. 'This collaboration represents another major step toward our goal of becoming the leading THC seltzer brand in the Southeast and beyond.' 'We are extremely excited to partner with Herbal Oasis as we enter this new and exciting category. We look forward to the future growth of both and plan to be an integral part of the wholesale distribution process. Our commitment to the responsible supply of Delta-9 products will drive our path forward,' said Billy Madison Beverage South Senior Director, Sales & Marketing. The THC beverage market continues to experience significant growth, with Brightfield estimating 50% growth in US Sales in 2025 to over $571 million. As consumers continue seeking alcohol alternatives that support presence, clarity, and connection, Herbal Oasis offers a refreshing, functional, and social-forward option—infused with THC, CBG, and functional mushrooms for a modern way to unwind. About Herbal Oasis Herbal Oasis is a premium THC-infused social seltzer that blends cannabinoids and nootropic mushrooms to deliver a fast-acting, functional beverage made for presence and connection. With an alcohol-free formula and wellness-forward ingredients, Oasis invites a better way to drink-one rooted in clarity, balance, and joy. More information can be found at Oasis is a subsidiary of cbdMD, Inc. About cbdMD, Inc. cbdMD, Inc. (NYSE American: YCBD) is one of the leading and most highly trusted and most recognized cannabidiol (CBD) brands with a comprehensive line of U.S. produced, THC-free 1 CBD products, and an array of Farm Act compliant Delta 9 products. Our Paw CBD brand of pet products includes veterinarian-formulated products, and our ATRx brand of natural functional mushroom support. To learn more about cbdMD and our comprehensive line of U.S. grown hemp products as well as our other brands, please visit or follow cbdMD on Instagram and Facebook, or visit one of the thousands of retail outlets that carry cbdMD's products. About Beverage South Beverage South is a leading beverage distributor serving Georgia and South Carolina, with operations in eight key markets including Albany, Athens, Augusta, Columbus, Griffin, Macon, Rome, and Columbia. Beverage South represents a diverse portfolio of top-tier beer, malt beverage, soda, and non-alcoholic brands. The company is committed to delivering exceptional service, fostering strong supplier partnerships, and driving growth through strategic investments in people, products, and market development. Forward-Looking Statements This press release contains certain forward-looking statements that are based upon current expectations and involve certain risks and uncertainties within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Such forward-looking statements can be identified using words such as ''should,'' ''may,'' ''intends,'' ''anticipates,'' ''believes,'' ''estimates,'' ''projects,'' ''forecasts,'' ''expects,'' ''plans,'' and ''proposes.'' These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, and other factors, some of which are beyond our control and difficult to predict. You are urged to carefully review and consider any cautionary statements, including but not limited to expectations on our ability to continue as a going concern, increasing our revenues, the development or future sales of Oasis products, regaining compliance with NYSE American continued listing requirements and other disclosures, including the statements made under the heading 'Risk Factors' in cbdMD, Inc.'s Annual Report on Form 10-K for the fiscal year ended September 30, 2024 as filed with the Securities and Exchange Commission (the 'SEC') on December 17, 2024, and our other filings with the SEC. All forward-looking statements, including Euromonitor international projections, involve significant risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements, many of which are generally outside the control of cbdMD, Inc. and are difficult to predict. cbdMD, Inc. does not undertake any duty to update any forward-looking statements except as may be required by law. The information which appears on our websites and our social media platforms, including, but not limited to, Instagram and Facebook, is not part of this press release. 1 THC-free is defined as below the level of detection using validated scientific analytical methods. Contact Information: cbdMD, Inc. Ronan Kennedy Chief Executive Officer and Chief Financial Officer [email protected] (704) 445-3064 To view the source version of this press release, please visit
Yahoo
15-05-2025
- Business
- Yahoo
cbdMD Delivers Continued Revenue Growth and Trend Towards Profitability in Second Fiscal Quarter
Successfully Completes Capital Structure Reset with Series A Preferred Conversion Charlotte, North Carolina--(Newsfile Corp. - May 15, 2025) - cbdMD, Inc. (NYSE American: YCBD), one of the nation's leading and most highly trusted and recognized CBD companies, and operator of the leading CBD brands cbdMD and Paw CBD, and Herbal Oasis today announced our financial results for the second quarter of fiscal year ended September 30, 2025. The Company reported continued year-over-year improvements in both revenue and earnings while completing a transformative restructuring of its capital structure. The Company delivered $4.8 million in revenue for the second quarter, up from $4.3 million in the prior year period. Operating loss narrowed significantly from $1.5 million to $0.48 million, reflecting disciplined expenses management and early traction from new growth initiatives. Ronan Kennedy, CEO and CFO of cbdMD, stated: "Our second quarter results build on the positive year over year momentum from the first quarter of fiscal 2025. We continue to execute on our growth plan while maintaining a lean, scalable structure. With fresh talent on the team and gaining traction from our Herbal Oasis beverage line, we're entering the second half of the year well positioned to continue the trend." "Our top priority this quarter was preparing for our annual shareholder meeting and shareholder proposals related to our plan to regain compliance with NYSE American Continued Listing Standards. Securing shareholder approval for the Series A Preferred conversion was a mission-critical milestone for our company and our shareholders. As previously reported, following shareholder approval, on May 7, 2025 the automatic conversion of our Series A Preferred Stock added nearly $7 million to our equity base, enabling us to exceed the $4 million minimum NYSE American continued listing standard. As part of this conversion, $6.7 million of accrued and future dividends as of March 31, 2025 were converted to equity upon the Series A Preferred conversion which we believe bring us into compliance with the NYSE American's continued listing standards. This positions cbdMD with a clean balance sheet, zero debt, and a simplified capital structure -- a strong foundation for growth and value creation," said Kennedy. "After two years of diligent work, we've restructured both our operations and our balance sheet. Today, we have a loyal customer base, an award-winning beverage brand, a simplified cap table, and the financial flexibility to execute our vision. This is an exciting reset for cbdMD." Highlights for the First Quarter of Fiscal 2025 and Strategic Updates Herbal Oasis Gains Momentum: cbdMD's hemp-derived THC beverage brand expanded distribution into Alabama, Florida, and North Carolina, tapping into one of the fastest-growing wellness categories. Award-Winning Product Line: All four flavors of Herbal Oasis received medals at the 2025 High Spirits Awards, presented by the L.A. Spirits Awards, affirming the brand's quality and consumer appeal. Series A Preferred Conversion Completed: On May 7, 2025, cbdMD executed a 1:13 conversion of its Series A Preferred Stock, eliminating $6.7 million in accrued dividend liability and adding equivalent equity value. Book Value Turnaround: Reported book value of equity as of March 31, 2025 was $0.67 million. On a non-GAAP pro forma basis, book value rises to approximately $7.3 million, post-conversion, satisfying NYSE American's equity listing requirements under Sections 1003(a)(i) and 1003(a)(ii). The Company is required to be in compliance with NYSE American Continued Listing Standards for 2 quarters to regain compliance with NYSE American Continued Listing Standards. Reverse Stock Split Executed: Concurrent with the conversion, the Company completed a 8:1 reverse stock split, resulting in approximately 8.9 million common shares outstanding as of May 15, 2025. Board Strengthened with Strategic Appointments: cbdMD added two new independent directors, bringing deep experience in capital markets, AI, sales, and marketing, to help guide the Company through its next growth phase. Financial Highlights from our Second Quarter of Fiscal Year 2025: Net sales totaled $4.7 million in the second quarter of fiscal 2025 or an increase of 8.6% compared to $4.4 million in fiscal 2024. Year to date revenues are up from $9.7 million to $9.9 million. Our gross margin increased year over year from 59% to 62% during the second quarter of fiscal 2025. Our loss from operations was $485,000 in the second quarter of fiscal 2025 as compared to a loss of $1.6 million in the prior year comparative period. Net Loss before preferred dividends totaled $0.5 million in the second quarter of fiscal 2025 as compared to a loss of $3.0 million in the prior year period. Our non-GAAP adjusted EBITDA ("EBITDA") loss from operations in the second quarter of fiscal 2025 was approximately $197,000 compared to our EBITDA loss from operations in fiscal 2024 of approximately $678,000. Net loss attributable to common shareholders for the second quarter of fiscal 2025 was approximately $1.48 million or a loss of $1.90 per share as compared to a net loss for the second quarter of fiscal 2024 of approximately $4.0 million, or $10.84 per share. The improvement in fiscal 2025 was principally attributable to ongoing management's efforts on reducing losses and plan for achieving profitability. At March 31, 2025, we had a working capital deficit of approximately ($3.7) million and cash on hand of approximately $1.8 million as compared to a working capital deficit of approximately ($2.2) million and cash on hand of approximately $2.4 million at September 30, 2024. Excluding $6.7 million and $4.7 million of respective accrued Series A dividend payments, adjusted net working capital totaled $2.8 million and $2.4 million for the respective periods. We reported direct to consumer (DTC) net sales of $3.6 million or 77% of total net sales in the second quarter of fiscal 2025, as compared with $3.6 million or 83% of total net sales in the second quarter of fiscal 2024. We reported wholesale net sales of $1.1 million or 23% of total net sales in the second quarter of fiscal 2025, as compared to $0.75 million the second quarter of fiscal 2024. We will host a conference call at 4:20 p.m., Eastern Time, on Thursday, May 15, 2025, to discuss our March 31, 2025, second fiscal quarter and year to date fiscal 2025 financial results and business progress. CONFERENCE CALL DETAILS Thursday May 15, 2025, 4:20 p.m. Eastern Time USA/Canada: 844-821-3524 International: 647-846-2919 Teleconference Replay dial in:USA/Canada: 855-669-9658 International: 412-317-0088 Replay Passcode: 7254091 Webcast/Webcast Replay link- available through May 15, 2026: About cbdMD, Inc. cbdMD, Inc. (NYSE American: YCBD) is one of the leading and most highly trusted and most recognized cannabidiol (CBD) brands with a comprehensive line of U.S. produced, THC-free1 CBD products, and an array of Farm Act compliant Delta 9 products. Our Paw CBD brand of pet products includes veterinarian-formulated products, our ATRx brand features functional mushroom products. In addition, we operate Herbal Oasis, a premium, award winning THC-infused social seltzer that blends cannabinoids and nootropic mushrooms to deliver a fast-acting, functional beverage made for presence and connection. With an alcohol-free formula and wellness-forward ingredients, Oasis invites a better way to drink-one rooted in clarity, balance, and joy. To learn more about cbdMD and our comprehensive line of U.S. grown, THC-free1 CBD and Full Spectrum products as well as our other brands, please visit or follow cbdMD on Instagram and Facebook, or visit one of the thousands of retail outlets that carry cbdMD's products. Forward-Looking Statements This press release contains certain forward-looking statements that are based upon current expectations and involve certain risks and uncertainties within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Such forward-looking statements can be identified using words such as ''should,'' ''may,'' ''intends,'' ''anticipates,'' ''believes,'' ''estimates,'' ''projects,'' ''forecasts,'' ''expects,'' ''plans,'' and ''proposes.'' These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, and other factors, some of which are beyond our control and difficult to predict. You are urged to carefully review and consider any cautionary statements, including but not limited to expectations on our ability to continue as a going concern, increasing our revenues, continued cost reductions, potential need for additional working capital, regaining compliance with NYSE American Continued Listing Standards, continued listing on the NYSE American, future profitability, development and sales of new products, and other disclosures, including the statements made under the heading "Risk Factors" in cbdMD, Inc.'s Annual Report on Form 10-K for the fiscal year ended September 30, 2024 as filed with the Securities and Exchange Commission (the "SEC") on December 17, 2024, and our other filings with the SEC. All forward-looking statements involve significant risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements, many of which are generally outside the control of cbdMD, Inc. and are difficult to predict. cbdMD, Inc. does not undertake any duty to update any forward-looking statements except as may be required by law. The information which appears on our websites and our social media platforms, including, but not limited to, Instagram and Facebook, is not part of this press release. 1 THC-free is defined as below the level of detection using validated scientific analytical methods. Non-GAAP Financial Measures This press release includes a financial measure that excludes the impact of certain items and therefore has not been calculated in accordance with U.S. generally accepted accounting principles ("GAAP"). cbdMD, Inc. has included adjusted loss from operations because management uses this measure to assess operating performance in order to highlight trends in our business that may not otherwise be apparent when relying on financial measures calculated in accordance with GAAP. The adjusted operating loss has not been prepared in accordance with GAAP. This non-GAAP financial measure should not be considered as an alternative to, or more meaningful than, net loss from operations as an indicator of our operating performance. Further, this non-GAAP financial measure, as presented by cbdMD, Inc., may not be comparable to similarly titled measures reported by other companies. cbdMD, Inc. has attached to this press release a reconciliation of this non-GAAP financial measure to its most directly comparable GAAP financial measure. cbdMD, BALANCE SHEETSMARCH 31, 2025 AND SEPTEMBER 30, 2024 (unaudited) March 31, September 30,2025 2024AssetsCash and cash equivalents $ 1,765,234$ 2,452,553Accounts receivable, net1,052,069 983,910Inventory, net2,662,705 2,365,187Inventory prepaid221,629 159,006Prepaid sponsorship11,478 21,754Prepaid expenses and other current assets479,312 406,674Total current assets6,192,427 6,389,084 Other assets: Property and equipment, net432,792 454,268Operating lease assets1,042,746 85,817Deposits for facilities62,708 62,708Intangible assets, net2,507,046 2,889,580Investment in other securities, non-current700,000 700,000Total other assets4,745,292 4,192,373 Total assets $ 10,937,719$ 10,581,457CONSOLIDATED BALANCE SHEETSMARCH 31, 2025 AND SEPTEMBER 30, 2024(continued) March 31, September 30,2025 2024Liabilities and shareholders' equity Current liabilities: Accounts payable $ 1,287,789$ 1,541,108Accrued expenses609,674 632,674Accrued dividends6,672,000 4,671,000Deferred revenue557,353 503,254Operating leases - current portion744,961 98,696Convertible notes, at fair value- 1,171,308Total current liabilities9,871,777 8,618,040 Long term liabilities: Operating leases - long term portion400,144 -Total long term liabilities400,144 - Total liabilities10,271,921 8,618,040 cbdMD, Inc. shareholders' equity: Preferred stock, authorized 50,000,000 shares, $0.001 par value, 5,000,000 and 5,000,000 shares issued and outstanding, respectively5,000 5,000Common stock, authorized 150,000,000 shares, $0.001 par value, 783,355 and 492,383 shares issued and outstanding, respectively783 492Additional paid in capital185,194,577 184,033,012Comprehensive other expense- (7,189 ) Accumulated deficit(184,534,562 )(182,067,898 ) Total cbdMD, Inc. shareholders' equity665,798 1,963,417 Total liabilities and shareholders' equity $ 10,937,719$ 10,581,457cbdMD, STATEMENTS OF OPERATIONSFOR THE THREE AND SIX MONTHS ENDED MARCH 31, 2025 and 2024(unaudited)Three Months Ended March 31, Six Months Ended March 31, 2025 2024 2025 2024Gross Sales$ 4,749,426$ 4,816,444$ 9,862,902$ 10,192,075Allowances - (439,926) - (440,152)Total Net Sales 4,749,426 4,376,518 9,862,902 9,751,923Cost of sales 1,790,062 1,795,790 3,502,929 3,613,698Gross Profit 2,959,364 2,580,728 6,359,973 6,138,225Operating expenses 3,445,180 4,131,719 6,932,061 8,755,053Loss from operations (485,816 )(1,550,991 )(572,088 )(2,616,828 ) Decrease of contingent liability - 4,828 - 74,580Decrease (increase) in fair value of convertible debt (2,583 )(1,446,000 )87,380 (1,446,000 ) Interest expense (income) 7,642 (18,399 )19,046 (18,817 ) Loss before provision for income taxes (480,757 )(3,010,562 )(465,662 )(4,007,065 ) Net loss (480,757 )(3,010,562 )(465,662 )(4,007,065 ) Preferred dividends 1,000,500 1,000,500 2,001,001 2,001,000 Net Loss attributable to cbdMD, Inc. common shareholders$ (1,481,257 ) $ (4,011,062 ) $ (2,466,663 ) $ (6,008,065 ) Net Loss per share: Basic and diluted earnings per share$ (1.90 ) $ (10.84 ) $ (3.67 ) $ (16.23 ) Weighted average number of shares Basic and Diluted: 778,409 370,132 672,558 370,125 cbdMD, STATEMENTS OF COMPREHENSIVE LOSSFOR THE THREE AND SIX MONTHS ENDED MARCH 31, 2025 and 2024(unaudited)Three Months Ended March 31, Six Months Ended March 31, 2025 2024 2025 2024 Net Loss$ (480,757 ) $ (3,010,562 ) $ (465,662 ) $ (4,007,065 ) Comprehensive Loss (480,757 )(3,010,562 )(465,662 )(4,007,065 ) Preferred dividends (1,000,500 )(1,000,500 )(2,001,001 )(2,001,000 ) Comprehensive Loss attributable to cbdMD, inc. common shareholders$ (1,481,257 ) $ (4,011,062 ) $ (2,466,663 ) $ (6,008,065 ) cbdMD, STATEMENT OF CASH FLOWSFOR THE SIX MONTHS ENDED MARCH 31, 2025 and 2024(unaudited)March 31, March 31, 2025 2024 Cash flows from operating activities: Net Loss$ (465,662 ) $ (4,007,065 ) Adjustments to reconcile net loss to net cash used by operating activities: Stock based compensation - 2,852Restricted stock expense 2,868 992Issuance of stock for services 82,250 -Amortization 382,534 345,684Depreciation 201,369 228,615Decrease in contingent liability - (74,580 ) Increase in fair value of convertible debt (87,380 )1,446,000Amortization of operating lease asset 330,969 584,574Changes in operating assets and liabilities: Accounts receivable (67,408 )301,132Deposits - 6,505Inventory (297,518 )878,967Prepaid inventory (62,623 )(95,119 ) Prepaid expenses and other current assets (62,361 )(164,404 ) Accounts payable and accrued expenses (277,135 )449,287Operating lease liability (241,489 )(628,891 ) Deferred revenue / customer deposits 54,160 (84,497 ) Cash flows from operating activities (507,426 )(809,948 ) Cash flows from investing activities: Purchase of property and equipment (179,893 )(180,015 ) Cash flows from investing activities (179,893 )(180,015 ) Cash flows from financing activities: Proceeds from issuance of common stock - 50,000Note payable - 1,247,499Cash flows from financing activities - 1,297,499Net increase (decrease) in cash (687,319 )307,536Cash and cash equivalents, beginning of period 2,452,553 1,797,860Cash and cash equivalents, end of period$ 1,765,234$ 2,105,396 Supplemental Disclosures of Cash Flow Information: 2025 2024 Cash Payments for: Interest expense$ 19,046$ 18,817 Non-cash financing/investing activities: Issuance of shares for conversion of debt and accrued interest$ 1,079,639$ -Issuance of share for services$ 82,250$ -Change in lease asset related to extinguishment of HQ lease and new warehouse lease$ (1,723,544 ) $ -Preferred dividends accrued but not paid$ 2,001,001$ 1,000,501 cbdMD, FINANCIAL INFORMATIONFOR THE THREE AND SIX MONTHS ENDED MARCH 31, 2025 and 2024(unaudited)Three Months Ended March 31, Six Months Ended March 31, 2025 2024 2025 2024 GAAP loss from operations$ (485,816 ) $ (1,550,991 ) $ (572,088 ) $ (2,616,828 ) Adjustments: Depreciation & Amortization 285,896 290,592 583,903 574,299Employee and director stock compensation (1) 1,934 11,944 5,016 28,486Mergers and Acquisitions and financing transaction expenses (2) - 58,239 - 125,838Non-cash expense incurred as a credit (3) 439,926 - 439,926Non-cash accelerated amortization of expense related to terminated IT contracts 72,101 - 72,101Non-GAAP adjusted income (loss) from operations$ (197,986 ) $ (678,189 ) $ 16,831$ (1,376,178 ) (1) Represents depreciation of property, plant and equipment and amortization of the Company's intangible assets.(2) Represents non-cash expense related to options, warrants, restricted stock expenses that have been amortized during the period.(3) Represents non-cash expense incurred as a credit provided to GNC to replace expired product. Contacts: Investors:cbdMD, Kennedy Chief Financial OfficerIR@ 445-3064 To view the source version of this press release, please visit Sign in to access your portfolio
Yahoo
07-05-2025
- Business
- Yahoo
Herbal Oasis Expands Southeast Presence with New Distribution Agreement in North Carolina
Charlotte, North Carolina--(Newsfile Corp. - May 7, 2025) - Herbal Oasis ("Oasis"), the hemp derived THC-infused social seltzer brand redefining how people connect, unwind, and celebrate life, is now proud to be distributed by Carolina Premium Beverage, serving Charlotte NC and surrounding counties. Starting in May, consumers will be able to find Oasis on shelves across North Carolina. This milestone marks Oasis's entrance into its third state in two months, following the successful launches into Alabama and Florida. The brand continues to build significant momentum as it expands distribution throughout the Southeast. A New Era of Social Beverages Oasis is crafted for the sober-curious, health-conscious, and socially active, and combines hemp-derived THC, CBG, and functional mushrooms to create a vibrant, elevated experience-without the regret. As consumers move toward alternative choices to alcohol to relax, Oasis offers a refreshing path forward: one that feels good, tastes great, and brings people together. "Partnering with Carolina Premium Beverage is exciting for us. This allows us to better serve our customers and accelerate door openings in our home territory of Charlotte. It is another step in driving our growth in the Southeast," said Ronan Kennedy, CEO of cbdMD, parent company of Herbal Oasis. "Their deep market reach and proven track record make them an ideal partner as we accelerate Oasis's growth across the Southeast." About Herbal Oasis Herbal Oasis is a premium THC-infused social seltzer that blends cannabinoids and nootropic mushrooms to deliver a fast-acting, functional beverage made for presence and connection. With an alcohol-free formula and wellness-forward ingredients, Oasis invites a better way to drink-one rooted in clarity, balance, and joy. More information can be found at Oasis is a subsidiary of cbdMD, Inc. About cbdMD, Inc. cbdMD, Inc. (NYSE American: YCBD) (NYSE American: YCBDpA) is one of the leading and most highly trusted and most recognized cannabidiol (CBD) brands with a comprehensive line of U.S. produced, THC-free1 CBD products, and an array of Farm Act compliant Delta 9 products. Our Paw CBD brand of pet products includes veterinarian-formulated products, and our ATRx brand of natural functional mushroom support. To learn more about cbdMD and our comprehensive line of U.S. grown, THC-free1 CBD oil and Full Spectrum products as well as our other brands, please visit or follow cbdMD on Instagram and Facebook, or visit one of the thousands of retail outlets that carry cbdMD's products.
Yahoo
24-04-2025
- Business
- Yahoo
Herbal Oasis Wins National Recognition at the 2025 High Spirits Awards
Charlotte, North Carolina--(Newsfile Corp. - April 24, 2025) - Herbal Oasis, a rising star in the alternative hemp beverage space, has earned national acclaim with a Gold Medal for Mango Bliss, Silver Medal for both Lemon Lift and Tropical Twist and a Bronze Medal for Berry Fusion at the 2025 High Spirits Awards, a leading showcase of excellence in cannabinoid-infused drinks hosted by the L.A. Spirits Awards in California. To view an enhanced version of this graphic, please visit: Herbal Oasis Social Tonic was awarded in the "Other Infused Beverage Products" category, a distinction that highlights unique formats pushing the edge of THC beverage innovation. The recognition comes just four months after the brand's national launch, marking a fast ascent for a beverage positioned as a stylish, non-alcoholic alternative for social settings. "We created Herbal Oasis for people looking for a better way to connect-as an alternative to alcohol," said Ronan Kelly, CEO of cbdM. "Winning this award validates what our community has been telling us: it tastes great, it feels great, and it fits the vibe." Launched at the end of 2024, Herbal Oasis was inspired by the growing movement toward low-dose, social THC consumption, especially among health-conscious adults looking for alternatives to traditional cocktails or beer. Hemp-derived THC beverages are one of the fastest growing consumer beverage categories. Euromonitor International estimates sales of hemp-derived THC beverages more than doubled in 2024 and are projected to balloon to $4.1 billion by 2028. Each can of Oasis combines hemp-derived THC, CBG, and functional mushrooms to create a vibrant, elevated experience-without regret. Oasis began hitting shelves in Alabama, Florida, and North Carolina in late March, with additional locations launching throughout spring and summer. Oasis is also available for nationwide delivery from The High Spirits Awards, founded by the creators of the L.A. Spirits Awards, evaluates products across 11 infused beverage categories. Winners are selected by a panel of experienced beverage professionals based on flavor, balance, packaging, and overall drinking experience. Medal designations range from Platinum to Bronze, with Best-in-Show honors reserved for the top of each category. About Herbal Oasis Herbal Oasis is a premium THC-infused social seltzer that blends cannabinoids and nootropic mushrooms to deliver a fast-acting, functional beverage made for presence and connection. With an alcohol-free formula and wellness-forward ingredients, Oasis invites a better way to drink-one rooted in clarity, balance, and joy. More information can be found at Oasis is a subsidiary of cbdMD, Inc. To learn more or find a retailer near you, visit: About cbdMD, Inc. cbdMD, Inc. (NYSE American: YCBD) (NYSE American: YCBDpA) is one of the leading and most highly trusted and most recognized cannabidiol (CBD) brands with a comprehensive line of U.S. produced, THC-free1 CBD products, and an array of Farm Act compliant Delta 9 products. Our Paw CBD brand of pet products includes veterinarian-formulated products, and our ATRx brand of natural functional mushroom support. To learn more about cbdMD and our comprehensive line of U.S. grown, THC-free1 CBD oil and Full Spectrum products as well as our other brands, please visit or follow cbdMD on Instagram and Facebook, or visit one of the thousands of retail outlets that carry cbdMD's products. Forward-Looking Statements This press release contains certain forward-looking statements that are based upon current expectations and involve certain risks and uncertainties within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Such forward-looking statements can be identified using words such as ''should,'' ''may,'' ''intends,'' ''anticipates,'' ''believes,'' ''estimates,'' ''projects,'' ''forecasts,'' ''expects,'' ''plans,'' and ''proposes.'' These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, and other factors, some of which are beyond our control and difficult to predict. You are urged to carefully review and consider any cautionary statements, including but not limited to expectations on our ability to continue as a going concern, increasing our revenues, the development or future sales of Oasis products, regaining compliance with NYSE American continued listing requirements and other disclosures, including the statements made under the heading "Risk Factors" in cbdMD, Inc.'s Annual Report on Form 10-K for the fiscal year ended September 30, 2024 as filed with the Securities and Exchange Commission (the "SEC") on December 17, 2024, and our other filings with the SEC. All forward-looking statements, including Euromonitor international projections, involve significant risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements, many of which are generally outside the control of cbdMD, Inc. and are difficult to predict. cbdMD, Inc. does not undertake any duty to update any forward-looking statements except as may be required by law. The information which appears on our websites and our social media platforms, including, but not limited to, Instagram and Facebook, is not part of this press release. 1 THC-free is defined as below the level of detection using validated scientific analytical methods. Contact Information: cbdMD, KennedyChief Executive Officer and Chief Financial OfficerIR@ 445-3064 Media Contact: Madison Fero, cbdMD, 980-240-5727, To view the source version of this press release, please visit Sign in to access your portfolio
Associated Press
08-04-2025
- Business
- Associated Press
Herbal Oasis Announces Distribution Agreement to Launch Statewide in Alabama and Select Florida Panhandle Markets
Charlotte, North Carolina--(Newsfile Corp. - April 8, 2025) - Herbal Oasis ('Oasis'), the hemp derived THC-infused social seltzer brand redefining how people connect, unwind, and celebrate life, is proud to announce that starting in late March, Oasis began arriving on shelves across Alabama and select counties in the Florida Panhandle, making it easier for people to grab Oasis's premium, alcohol-free beverage made for presence, clarity, and connection. A New Era of Social Beverages Oasis, a hemp derived THC-infused social seltzer, is designed to redefine how people connect, unwind, and celebrate life. Crafted for the sober-curious, health-conscious, and socially active, Oasis combines hemp-derived THC, CBG, and functional mushrooms to create a vibrant, elevated experience-without the regret. As consumers move toward alternative choices to alcohol to relax, Oasis offers a refreshing path forward: one that feels good, tastes great, and brings people together. 'We're excited to expand distribution into Alabama and Florida-this is a major launchpad for our mission to make Oasis the go-to beverage for modern socializing,' said Ronan Kennedy, CEO of cbdMD, the parent company of Oasis. 'Consumers are energized by and embracing the shift in the beverage landscape, and Oasis is perfectly positioned to lead the way.' London-based data analytics and research firm Euromonitor International estimates sales of hemp-derived THC beverages more than doubled in 2024 and are projected to balloon to $4.1 billion by 2028, an massive 1,600% increase from $239 million in 2023. Formulated for Feel-Good Connection Each 12-ounce can of Oasis is infused with: Rolling Out in Key Locations Across Alabama and the Florida Panhandle Oasis will be available in grocery chains, convenience stores, boutique wellness shops, and hospitality venues across major Alabama cities like Birmingham, Mobile, Huntsville, and college towns like Tuscaloosa and Auburn, as well as resort destinations and nightlife hubs in the Florida Panhandle. This includes support for on-premise accounts such as bars, restaurants, and lounges. Availability Oasis began hitting shelves in Alabama and Florida in late-March, with additional locations launching throughout spring and summer. About Herbal Oasis Herbal Oasis is a premium THC-infused social seltzer that blends cannabinoids and nootropic mushrooms to deliver a fast-acting, functional beverage made for presence and connection. With an alcohol-free formula and wellness-forward ingredients, Oasis invites a better way to drink-one rooted in clarity, balance, and joy. More information can be found at Oasis is a subsidiary of cbdMD, Inc. About cbdMD, Inc. cbdMD, Inc. (NYSE American: YCBD) (NYSE American: YCBDpA) is one of the leading and most highly trusted and most recognized cannabidiol (CBD) brands with a comprehensive line of U.S. produced, THC-free1 CBD products, and an array of Farm Act compliant Delta 9 products. Our Paw CBD brand of pet products includes veterinarian-formulated products, and our ATRx brand of natural functional mushroom support. To learn more about cbdMD and our comprehensive line of U.S. grown, THC-free 1 CBD oil and Full Spectrum products as well as our other brands, please visit or follow cbdMD on Instagram and Facebook, or visit one of the thousands of retail outlets that carry cbdMD's products. Forward-Looking Statements This press release contains certain forward-looking statements that are based upon current expectations and involve certain risks and uncertainties within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Such forward-looking statements can be identified using words such as ''should,'' ''may,'' ''intends,'' ''anticipates,'' ''believes,'' ''estimates,'' ''projects,'' ''forecasts,'' ''expects,'' ''plans,'' and ''proposes.'' These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, and other factors, some of which are beyond our control and difficult to predict. You are urged to carefully review and consider any cautionary statements, including but not limited to expectations on our ability to continue as a going concern, increasing our revenues, the development or future sales of Oasis products, regaining compliance with NYSE American continued listing requirements and other disclosures, including the statements made under the heading 'Risk Factors' in cbdMD, Inc.'s Annual Report on Form 10-K for the fiscal year ended September 30, 2024 as filed with the Securities and Exchange Commission (the 'SEC') on December 17, 2024, and our other filings with the SEC. All forward-looking statements, including Euromonitor international projections, involve significant risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements, many of which are generally outside the control of cbdMD, Inc. and are difficult to predict. cbdMD, Inc. does not undertake any duty to update any forward-looking statements except as may be required by law. The information which appears on our websites and our social media platforms, including, but not limited to, Instagram and Facebook, is not part of this press release. 1 THC-free is defined as below the level of detection using validated scientific analytical methods. cbdMD, Inc.
